Last reviewed 2026-04-19 · How we verify

BENEXATE

Phase 2 active Small molecule

BENEXATE is a benexate drug. It is currently in Phase 2 development.

Benexate works by inhibiting gastric acid secretion, but the exact mechanism of action is not well understood.

Benexate is a small molecule drug in the benexate class, but specific details about its target, indications, and pharmacokinetics are unknown. Its commercial status, including patent status and generic availability, is also unclear. As a result, it is difficult to provide a comprehensive summary of benexate's clinical use and safety profile. Further research is needed to determine its potential therapeutic applications and key safety considerations. Without more information, it is challenging to assess benexate's place in modern pharmacotherapy.

Likelihood of approval

13.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Cardiovascular Phase 3 risk -2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BENEXATE
Drug class	benexate
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 2

Mechanism of action

Think of it like a fire extinguisher for your stomach. Benexate helps reduce the amount of acid produced in the stomach, which can help alleviate symptoms of conditions like heartburn and acid reflux. This can make it easier to digest food and reduce discomfort.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BENEXATE CI brief — competitive landscape report
BENEXATE updates RSS · CI watch RSS

Frequently asked questions about BENEXATE

What is BENEXATE?

BENEXATE is a benexate drug.

How does BENEXATE work?

Benexate works by inhibiting gastric acid secretion, but the exact mechanism of action is not well understood.

What drug class is BENEXATE in?

BENEXATE belongs to the benexate class. See all benexate drugs at /class/benexate.

What development phase is BENEXATE in?

BENEXATE is in Phase 2.

Drug class: All benexate drugs
Therapeutic area: All drugs in Cardiovascular

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing